Luke Howard

机构：Imperial College Healthcare NHS Trust, Hammersmith Hospital, Lung Institute, Imperial College London · ORCID：0000-0003-2822-210X

发表论文 504 篇 · 总被引 19393 次 · h-index 70

代表论文

• Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study (2025 · American Journal of Respiratory and Critical Care Medicine · 被引 27)
• Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in Pulmonary Hypertension in Interstitial Lung Disease: A PVRI GoDeep Meta-Registry Analysis (2025 · American Journal of Respiratory and Critical Care Medicine · 被引 15)
• Prognostic value of cardiopulmonary exercise testing in pulmonary arterial hypertension (2025 · European Respiratory Journal · 被引 12)
• Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2025 · The Lancet Infectious Diseases · 被引 11)
• Diagnostic MicroRNA Signatures to Support Classification of Pulmonary Hypertension (2025 · Circulation Genomic and Precision Medicine · 被引 10)
• Characteristics, Prognosis, and European Society of Cardiology and European Respiratory Society Risk Stratification in Patients With Obesity and Pulmonary Arterial Hypertension (2025 · CHEST Journal · 被引 10)